Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Akshay Vaishnaw. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Akshay Vaishnaw har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:SRRK / Scholar Rock Holding Corporation | President of R&D, Director | 616 205 |
US:ALNY / Alnylam Pharmaceuticals, Inc. | President | 22 774 |
US:EDIT / Editas Medicine, Inc. | Director | 11 538 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Akshay Vaishnaw. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp EDIT / Editas Medicine, Inc. - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i EDIT / Editas Medicine, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel EDIT / Editas Medicine, Inc. - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i EDIT / Editas Medicine, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internkjøp SRRK / Scholar Rock Holding Corporation - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i EDIT / Editas Medicine, Inc.. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel SRRK / Scholar Rock Holding Corporation - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i EDIT / Editas Medicine, Inc.. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Akshay Vaishnaw som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-05-30 |
|
4 | SRRK |
Scholar Rock Holding Corp
Common Stock |
S - Sale | X | −1 620 | 616 205 | −0,26 | 30,01 | −48 612 | 18 490 587 |
2025-05-30 |
|
4 | SRRK |
Scholar Rock Holding Corp
Common Stock |
S - Sale | X | −5 130 | 617 825 | −0,82 | 29,63 | −152 000 | 18 305 969 |
2025-04-29 |
|
4 | SRRK |
Scholar Rock Holding Corp
Common Stock |
A - Award | 500 000 | 622 955 | 406,65 | ||||
2025-04-29 |
|
4 | SRRK |
Scholar Rock Holding Corp
Common Stock |
A - Award | 100 000 | 122 955 | 435,63 | ||||
2024-07-01 |
|
4 | SRRK |
Scholar Rock Holding Corp
Common Stock |
A - Award | 13 500 | 22 955 | 142,78 | ||||
2023-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −192 | 22 774 | −0,84 | 189,31 | −36 348 | 4 311 346 | |
2023-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −17 | 22 966 | −0,07 | 188,40 | −3 203 | 4 326 794 | |
2023-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −101 | 22 983 | −0,44 | 187,37 | −18 924 | 4 306 325 | |
2023-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 107 | 23 084 | −4,58 | 186,39 | −206 334 | 4 302 627 | |
2023-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 869 | 24 191 | −7,17 | 185,54 | −346 774 | 4 488 398 | |
2023-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −771 | 26 060 | −2,87 | 184,70 | −142 404 | 4 813 282 | |
2023-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 3 859 | 26 831 | 16,80 | ||||
2023-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 5 082 | 22 972 | 28,41 | ||||
2023-04-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −168 | 17 890 | −0,93 | 197,08 | −33 109 | 3 525 761 | |
2023-04-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −104 | 18 058 | −0,57 | 195,65 | −20 348 | 3 533 048 | |
2023-04-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −1 013 | 18 162 | −5,28 | 194,94 | −197 474 | 3 540 500 | |
2023-04-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −910 | 19 175 | −4,53 | 193,93 | −176 476 | 3 718 608 | |
2023-04-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | −197 | 20 085 | −0,97 | 193,18 | −38 056 | 3 880 020 | |
2023-04-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 5 312 | 20 282 | 35,48 | ||||
2023-02-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 302 | 14 970 | −22,32 | 217,05 | −933 749 | 3 249 238 |
2023-02-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −19 447 | 19 272 | −50,23 | 216,38 | −4 207 942 | 4 170 075 |
2023-02-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 279 | 38 719 | −20,98 | 215,59 | −2 216 050 | 8 347 429 |
2023-02-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 307 | 48 998 | −4,50 | 214,28 | −494 344 | 10 499 291 |
2023-02-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 709 | 51 305 | −3,22 | 213,13 | −364 239 | 10 934 635 |
2023-02-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 30 913 | 53 014 | 139,87 | 63,00 | 1 947 519 | 3 339 882 |
2022-12-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −1 324 | 22 101 | −5,65 | 226,20 | −299 489 | 4 999 246 | |
2022-12-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 2 368 | 23 425 | 11,25 | 42,22 | 99 977 | 989 004 | |
2022-12-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 587 | 21 057 | 8,15 | 63,00 | 99 981 | 1 326 591 | |
2022-12-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 124 | 19 470 | 6,13 | 88,95 | 99 980 | 1 731 856 | |
2022-08-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −198 | 18 346 | −1,07 | 210,75 | −41 728 | 3 866 420 | |
2022-08-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −180 | 18 544 | −0,96 | 210,66 | −37 919 | 3 906 479 | |
2022-08-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −195 | 18 724 | −1,03 | 210,22 | −40 993 | 3 936 159 | |
2022-08-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −5 479 | 18 919 | −22,46 | 189,76 | −1 039 695 | 3 590 069 | |
2022-08-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 3 859 | 24 398 | 18,79 | ||||
2022-08-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 4 241 | 20 539 | 26,02 | ||||
2022-08-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 5 083 | 16 298 | 45,32 | ||||
2022-05-27 |
|
4 | SRRK |
Scholar Rock Holding Corp
Stock Option (Right to Buy) |
A - Award | 28 000 | 28 000 | |||||
2022-02-25 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 29 842 | 29 842 | |||||
2022-01-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 22 380 | 22 380 | |||||
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −303 | 11 215 | −2,63 | 195,11 | −59 118 | 2 188 159 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −145 | 11 518 | −1,24 | 193,67 | −28 082 | 2 230 691 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −126 | 11 663 | −1,07 | 193,37 | −24 365 | 2 255 274 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −73 | 11 789 | −0,62 | 192,25 | −14 034 | 2 266 435 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 000 | 11 862 | −7,77 | 191,45 | −191 450 | 2 270 980 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −125 | 12 862 | −0,96 | 190,86 | −23 858 | 2 454 841 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −142 | 12 987 | −1,08 | 190,39 | −27 035 | 2 472 595 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −73 | 13 129 | −0,55 | 190,33 | −13 894 | 2 498 843 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 | 13 202 | −0,04 | 190,27 | −951 | 2 511 945 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −144 | 13 207 | −1,08 | 190,02 | −27 363 | 2 509 594 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −144 | 13 351 | −1,07 | 189,24 | −27 251 | 2 526 543 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 | 13 495 | −0,06 | 189,18 | −1 513 | 2 552 984 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −73 | 13 503 | −0,54 | 189,01 | −13 798 | 2 552 202 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −127 | 13 576 | −0,93 | 188,26 | −23 909 | 2 555 818 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −130 | 13 703 | −0,94 | 187,35 | −24 356 | 2 567 257 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −137 | 13 833 | −0,98 | 187,08 | −25 630 | 2 587 878 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −124 | 13 970 | −0,88 | 186,22 | −23 091 | 2 601 493 |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −122 | 14 094 | −0,86 | 186,48 | −22 751 | 2 628 249 | |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −1 | 14 216 | −0,01 | 190,50 | −190 | 2 708 148 | |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −2 415 | 14 217 | −14,52 | 189,13 | −456 749 | 2 688 861 | |
2021-12-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 5 417 | 16 632 | 48,30 | ||||
2021-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2013 (right to buy) |
M - Exercise | X | −10 834 | 10 832 | −50,00 | |||
2021-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 834 | 11 215 | −49,14 | 200,00 | −2 166 800 | 2 243 000 |
2021-08-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 10 834 | 22 049 | 96,60 | 63,00 | 682 542 | 1 389 087 |
2021-06-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −970 | 2 368 | −29,06 | |||
2021-06-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2013 (right to buy) |
M - Exercise | X | −10 834 | 21 666 | −33,34 | |||
2021-06-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −14 708 | 11 215 | −56,74 | 175,00 | −2 573 900 | 1 962 625 |
2021-06-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 970 | 25 923 | 3,89 | 42,22 | 40 953 | 1 094 469 |
2021-06-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 10 834 | 24 953 | 76,73 | 63,00 | 682 542 | 1 572 039 |
2021-06-07 |
|
4 | EDIT |
Editas Medicine, Inc.
Stock Option (right to buy) |
A - Award | 11 538 | 11 538 | |||||
2021-06-01 |
|
4 | SRRK |
Scholar Rock Holding Corp
Stock Option (Right to Buy) |
A - Award | 7 800 | 7 800 | |||||
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −107 | 14 119 | −0,75 | 138,48 | −14 817 | 1 955 199 |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −530 | 14 226 | −3,59 | 137,60 | −72 928 | 1 957 498 |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 892 | 14 756 | −11,36 | 136,84 | −258 901 | 2 019 211 |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −203 | 16 648 | −1,20 | 135,41 | −27 488 | 2 254 306 |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −85 | 16 851 | −0,50 | 134,56 | −11 438 | 2 267 528 | |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −2 266 | 16 936 | −11,80 | 131,75 | −298 546 | 2 231 318 | |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −417 | 19 202 | −2,13 | 140,02 | −58 388 | 2 688 664 |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −622 | 19 619 | −3,07 | 138,64 | −86 234 | 2 719 978 |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −989 | 20 241 | −4,66 | 137,60 | −136 086 | 2 785 162 |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 678 | 21 230 | −7,32 | 136,76 | −229 483 | 2 903 415 |
2021-04-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 5 083 | 22 908 | 28,52 | ||||
2021-02-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 28 800 | 28 800 | |||||
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −92 | 17 825 | −0,51 | 152,53 | −14 033 | 2 718 847 | |
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −1 618 | 17 917 | −8,28 | 156,00 | −252 408 | 2 795 052 | |
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 8 334 | 25 000 | 50,01 | ||||
2021-02-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 5 416 | 19 535 | 38,36 | ||||
2020-10-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −971 | 3 338 | −22,53 | |||
2020-10-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −971 | 14 119 | −6,43 | 140,00 | −135 940 | 1 976 660 |
2020-10-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 971 | 15 090 | 6,88 | 42,22 | 40 996 | 637 100 |
2020-06-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −970 | 4 309 | −18,37 | |||
2020-06-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −195 | 14 119 | −1,36 | 152,97 | −29 829 | 2 159 783 |
2020-06-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −334 | 14 314 | −2,28 | 152,22 | −50 841 | 2 178 877 |
2020-06-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −180 | 14 648 | −1,21 | 150,34 | −27 061 | 2 202 180 |
2020-06-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −83 | 14 828 | −0,56 | 149,09 | −12 374 | 2 210 707 |
2020-06-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −178 | 14 911 | −1,18 | 148,48 | −26 429 | 2 213 985 |
2020-06-24 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 970 | 15 089 | 6,87 | 42,22 | 40 953 | 637 058 |
2020-06-18 |
|
4 | SRRK |
Scholar Rock Holding Corp
Stock Option (right to buy) |
A - Award | 13 000 | 13 000 | |||||
2020-06-12 |
|
4 | EDIT |
Editas Medicine, Inc.
Stock Option (right to buy) |
A - Award | 11 538 | 11 538 | |||||
2020-04-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −971 | 5 279 | −15,54 | |||
2020-04-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
M - Exercise | X | −21 000 | 0 | −100,00 | |||
2020-04-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −21 971 | 14 119 | −60,88 | 140,00 | −3 075 940 | 1 976 660 |
2020-04-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 971 | 36 090 | 2,76 | 42,22 | 40 996 | 1 523 720 |
2020-04-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 21 000 | 35 119 | 148,74 | 42,22 | 886 620 | 1 482 724 |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −98 | 14 119 | −0,69 | 106,52 | −10 439 | 1 503 956 | |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −2 415 | 14 217 | −14,52 | 104,75 | −252 971 | 1 489 231 | |
2020-04-09 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 5 417 | 16 632 | 48,30 | ||||
2020-02-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 27 623 | 27 623 | |||||
2020-02-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −18 750 | 6 250 | −75,00 | |||
2020-02-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
M - Exercise | X | −4 000 | 21 000 | −16,00 | |||
2020-02-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −23 708 | 11 215 | −67,89 | 125,00 | −2 963 500 | 1 401 875 |
2020-02-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 4 000 | 34 923 | 12,94 | 42,22 | 168 880 | 1 474 449 |
2020-02-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 18 750 | 30 923 | 154,03 | 42,22 | 791 625 | 1 305 569 |
2019-12-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 8 333 | 16 666 | 100,00 | ||||
2019-11-26 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2017 (right to buy) |
A - Award | 8 333 | 8 333 | |||||
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 25 000 | 33,33 | ||||
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 7 500 | 30 000 | 33,33 | ||||
2019-08-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 48 | 515 | 10,28 | ||||
2019-06-14 |
|
4 | EDIT |
Editas Medicine, Inc.
Stock Option (right to buy) |
A - Award | 11 538 | 11 538 | |||||
2019-06-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 18 750 | 50,00 | ||||
2019-06-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 51 | 467 | 12,26 | ||||
2019-06-07 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 21 | 416 | 5,32 | ||||
2019-05-23 |
|
4 | SRRK |
Scholar Rock Holding Corp
Stock Option (Right to Buy) |
A - Award | 20 316 | 20 316 | |||||
2019-03-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 32 500 | 32 500 | |||||
2018-09-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2016 (right to buy) |
A - Award | 6 250 | 12 500 | 100,00 | ||||
2018-09-28 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 7 500 | 22 500 | 50,00 | ||||
2018-08-23 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 7 500 | 15 000 | 100,00 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −766 | 12 173 | −5,92 | 90,95 | −69 668 | 1 107 134 | |
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 1 724 | 12 939 | 15,37 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option 2014 (right to buy) |
A - Award | 11 707 | 35 125 | 49,99 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option 2013 (right to buy) |
A - Award | 10 832 | 32 500 | 49,99 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 29 | 395 | 7,92 | ||||
2018-08-14 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
J - Other | 28 | 366 | 8,28 | ||||
2018-06-19 |
|
4 | EDIT |
Editas Medicine, Inc.
Stock Option (right to buy) |
A - Award | 11 538 | 11 538 | |||||
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −44 641 | 0 | −100,00 | |||
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −38 913 | 0 | −100,00 | |||
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −5 000 | 0 | −100,00 | |||
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 380 | 11 215 | −36,26 | 145,27 | −926 823 | 1 629 203 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −20 172 | 17 595 | −53,41 | 144,53 | −2 915 459 | 2 543 005 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −19 213 | 37 767 | −33,72 | 143,46 | −2 756 297 | 5 418 054 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −21 336 | 56 980 | −27,24 | 142,57 | −3 041 874 | 8 123 639 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −15 000 | 78 316 | −16,07 | 141,69 | −2 125 350 | 11 096 594 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 453 | 93 316 | −6,47 | 140,45 | −906 324 | 13 106 232 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 5 000 | 99 769 | 5,28 | 7,10 | 35 500 | 708 360 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 38 913 | 94 769 | 69,67 | 16,43 | 639 341 | 1 557 055 |
2018-03-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 44 641 | 55 856 | 398,05 | 18,66 | 833 001 | 1 042 273 |
2018-03-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2017-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Based Stock Option 2016 (right to buy) |
A - Award | 6 250 | 6 250 | |||||
2017-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
G - Gift | −320 | 11 215 | −2,77 | ||||
2017-11-08 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2015 (right to buy) |
A - Award | 7 500 | 7 500 | |||||
2017-11-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −33 666 | 0 | −100,00 | |||
2017-11-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 693 | 11 535 | −24,25 | 122,79 | −453 463 | 1 416 383 |
2017-11-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −17 755 | 15 228 | −53,83 | 121,69 | −2 160 606 | 1 853 095 |
2017-11-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 418 | 32 983 | −25,72 | 120,78 | −1 379 066 | 3 983 687 |
2017-11-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −800 | 44 401 | −1,77 | 119,79 | −95 832 | 5 318 796 |
2017-11-01 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 33 666 | 45 201 | 291,86 | 21,35 | 718 769 | 965 041 |
2017-09-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2013 (right to buy) |
A - Award | 10 834 | 10 834 | |||||
2017-07-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy) |
A - Award | 11 709 | 23 418 | 100,00 | ||||
2017-06-19 |
|
4 | EDIT |
Editas Medicine, Inc.
Stock Option (right to buy) |
A - Award | 11 538 | 11 538 | |||||
2017-06-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −328 | 33 666 | −0,96 | ||||
2017-06-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −1 340 | 44 641 | −2,91 | ||||
2017-06-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −430 | 11 535 | −3,59 | 74,31 | −31 953 | 857 166 | |
2017-06-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 340 | 11 965 | 12,61 | 18,66 | 25 004 | 223 267 | |
2017-06-15 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 328 | 10 625 | 3,19 | 21,35 | 7 003 | 226 844 | |
2017-05-25 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −11 000 | 33 994 | −24,45 | |||
2017-05-25 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 000 | 10 297 | −51,65 | 75,00 | −825 000 | 772 275 |
2017-05-25 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 11 000 | 21 297 | 106,83 | 21,35 | 234 850 | 454 691 |
2017-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −32 750 | 0 | −100,00 | |||
2017-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −11 000 | 44 994 | −19,64 | |||
2017-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 000 | 10 297 | −51,65 | 65,00 | −715 000 | 669 305 |
2017-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 11 000 | 21 297 | 106,83 | 21,35 | 234 850 | 454 691 |
2017-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −32 750 | 10 297 | −76,08 | 65,00 | −2 128 750 | 669 305 |
2017-05-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 32 750 | 43 047 | 318,05 | 31,39 | 1 028 022 | 1 351 245 |
2017-01-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −4 356 | 55 994 | −7,22 | ||||
2017-01-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −4 019 | 45 981 | −8,04 | ||||
2017-01-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −1 172 | 38 913 | −2,92 | ||||
2017-01-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −5 000 | 10 297 | −32,69 | 37,44 | −187 200 | 385 520 | |
2017-01-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4 356 | 15 297 | 39,81 | 21,35 | 93 001 | 326 591 | |
2017-01-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4 019 | 10 941 | 58,06 | 18,66 | 74 995 | 204 159 | |
2017-01-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 1 172 | 6 922 | 20,38 | 16,43 | 19 256 | 113 728 | |
2016-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 25 000 | 25 000 | |||||
2016-12-02 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −29 165 | 0 | −100,00 | |||
2016-12-02 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 500 | 5 750 | −20,69 | 46,14 | −69 208 | 265 298 |
2016-12-02 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −13 297 | 7 250 | −64,72 | 45,55 | −605 662 | 330 229 |
2016-12-02 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −14 368 | 20 547 | −41,15 | 44,34 | −637 127 | 911 126 |
2016-12-02 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 29 165 | 34 915 | 507,22 | 22,75 | 663 504 | 794 316 |
2016-07-29 |
|
4 | EDIT |
Editas Medicine, Inc.
Stock Option (right to buy) |
A - Award | 23 076 | 23 076 | |||||
2016-07-29 | 3 | EDIT |
Editas Medicine, Inc.
No securities are beneficially owned |
0 | ||||||||
2016-02-25 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 10 000 | 10 000 | |||||
2016-02-03 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance Stock Option 2014 (right to buy) |
A - Award | 11 709 | 11 709 | |||||
2015-12-22 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 30 000 | 30 000 | |||||
2015-11-30 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −835 | 29 165 | −2,78 | ||||
2015-11-30 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | −4 915 | 40 085 | −10,92 | ||||
2015-11-30 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 4 915 | 5 750 | 588,62 | 16,43 | 80 753 | 94 472 | |
2015-11-30 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | 835 | 835 | 22,75 | 18 996 | 18 996 | ||
2015-06-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −6 250 | 0 | −100,00 | |||
2015-06-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −2 500 | 5 000 | −33,33 | |||
2015-06-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −350 | 0 | −100,00 | 131,00 | −45 850 | |
2015-06-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 800 | 350 | −83,72 | 130,06 | −234 100 | 45 519 |
2015-06-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 667 | 2 150 | −55,37 | 128,79 | −343 479 | 276 895 |
2015-06-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 933 | 4 817 | −44,95 | 128,10 | −503 811 | 617 050 |
2015-06-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 2 500 | 8 750 | 40,00 | 7,10 | 17 750 | 62 125 |
2015-06-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 250 | 6 250 | 9,30 | 58 125 | 58 125 | |
2015-05-05 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
A - Award | 35 125 | 35 125 | |||||
2015-03-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −6 250 | 6 250 | −50,00 | |||
2015-03-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −2 500 | 7 500 | −25,00 | |||
2015-03-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −644 | 0 | −100,00 | 119,38 | −76 881 | |
2015-03-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 000 | 644 | −60,83 | 118,16 | −118 160 | 76 095 |
2015-03-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 080 | 1 644 | −55,85 | 117,35 | −244 088 | 192 923 |
2015-03-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 802 | 3 724 | −50,52 | 116,34 | −442 325 | 433 250 |
2015-03-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 224 | 7 526 | −13,99 | 115,29 | −141 115 | 867 673 |
2015-03-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 2 500 | 8 750 | 40,00 | 7,10 | 17 750 | 62 125 |
2015-03-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 250 | 6 250 | 9,30 | 58 125 | 58 125 | |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −6 251 | 12 500 | −33,34 | |||
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −1 875 | 0 | −100,00 | |||
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −2 500 | 10 000 | −20,00 | |||
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −100 | 0 | −100,00 | 95,00 | −9 500 | |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 090 | 100 | −98,07 | 94,40 | −480 514 | 9 440 |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 936 | 5 190 | −36,13 | 93,42 | −274 273 | 484 836 |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 900 | 8 126 | −18,95 | 92,33 | −175 420 | 750 244 |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −600 | 10 026 | −5,65 | 91,47 | −54 880 | 917 045 |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 2 500 | 10 626 | 30,77 | 7,10 | 17 750 | 75 445 |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 251 | 8 126 | 333,39 | 9,30 | 58 134 | 75 572 |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 1 875 | 1 875 | 9,14 | 17 138 | 17 138 | |
2014-12-16 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Performance-Based Stock Option (Right to Buy) |
A - Award | 10 834 | 10 834 | |||||
2014-09-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −6 250 | 18 751 | −25,00 | |||
2014-09-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −1 875 | 1 875 | −50,00 | |||
2014-09-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −2 500 | 12 500 | −16,67 | |||
2014-09-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −800 | 0 | −100,00 | 73,03 | −58 422 | |
2014-09-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 625 | 800 | −89,23 | 72,27 | −478 766 | 57 813 |
2014-09-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 200 | 7 425 | −30,12 | 71,34 | −228 275 | 529 669 |
2014-09-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 2 500 | 10 625 | 30,77 | 7,10 | 17 750 | 75 438 |
2014-09-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 250 | 8 125 | 333,33 | 9,30 | 58 125 | 75 562 |
2014-09-17 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 1 875 | 1 875 | 9,14 | 17 138 | 17 138 | |
2014-06-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −6 250 | 25 001 | −20,00 | |||
2014-06-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −1 875 | 3 750 | −33,33 | |||
2014-06-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −2 500 | 15 000 | −14,29 | |||
2014-06-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 127 | 0 | −100,00 | 69,97 | −568 620 | |
2014-06-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 498 | 8 127 | −23,51 | 69,33 | −173 178 | 563 418 |
2014-06-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 250 | 10 625 | 142,86 | 9,30 | 58 125 | 98 812 |
2014-06-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 2 500 | 4 375 | 133,33 | 7,10 | 17 750 | 31 062 |
2014-06-19 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 1 875 | 1 875 | 9,14 | 17 138 | 17 138 | |
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −22 145 | 0 | −100,00 | |||
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −6 249 | 31 251 | −16,66 | |||
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −1 875 | 5 625 | −25,00 | |||
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −2 500 | 17 500 | −12,50 | |||
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 944 | 0 | −100,00 | 75,15 | −146 094 | |
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −22 044 | 1 944 | −91,90 | 74,08 | −1 633 110 | 144 019 |
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 781 | 23 988 | −26,80 | 73,34 | −644 020 | 1 759 337 |
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 2 500 | 32 769 | 8,26 | 7,10 | 17 750 | 232 660 |
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 249 | 30 269 | 26,02 | 9,30 | 58 116 | 281 502 |
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 1 875 | 24 020 | 8,47 | 9,14 | 17 138 | 219 543 |
2014-03-20 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 22 145 | 22 145 | 12,96 | 286 999 | 286 999 | |
2014-02-25 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
I - Other | −2 615 | 0 | −100,00 | 90,10 | −235 612 | ||
2014-01-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −700 | 0 | −100,00 | 87,44 | −61 208 | |
2014-01-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 100 | 700 | −61,11 | 86,60 | −95 260 | 60 620 |
2014-01-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 221 | 1 800 | −70,10 | 85,77 | −362 056 | 154 395 |
2014-01-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 869 | 6 021 | −23,69 | 84,57 | −158 065 | 509 207 |
2014-01-27 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
F - Taxes | −4 698 | 7 890 | −37,32 | 89,49 | −420 424 | 706 076 | |
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 32 500 | 32 500 | |||||
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −18 480 | 22 145 | −45,49 | |||
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −9 980 | 12 588 | −44,22 | 61,40 | −612 762 | 772 891 |
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −8 500 | 22 568 | −27,36 | 60,59 | −514 999 | 1 367 352 |
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 18 480 | 31 068 | 146,81 | 12,96 | 239 501 | 402 641 |
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −6 250 | 37 500 | −14,29 | |||
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −3 750 | 7 500 | −33,33 | |||
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −5 000 | 20 000 | −20,00 | |||
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 256 | 12 588 | −25,27 | 60,78 | −258 669 | 765 068 |
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 744 | 16 844 | −38,94 | 60,19 | −646 629 | 1 013 758 |
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 5 000 | 27 588 | 22,14 | 7,10 | 35 500 | 195 875 |
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 250 | 22 588 | 38,25 | 9,30 | 58 125 | 210 068 |
2013-12-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 3 750 | 16 338 | 29,79 | 9,14 | 34 275 | 149 329 |
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −6 250 | 43 750 | −12,50 | |||
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −700 | 12 588 | −5,27 | 58,18 | −40 724 | 732 333 |
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −5 550 | 13 288 | −29,46 | 57,39 | −318 514 | 762 598 |
2013-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 250 | 18 838 | 49,65 | 9,30 | 58 125 | 175 193 |
2013-06-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −6 250 | 50 000 | −11,11 | |||
2013-06-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −3 750 | 11 250 | −25,00 | |||
2013-06-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −5 000 | 25 000 | −16,67 | |||
2013-06-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −100 | 12 588 | −0,79 | 31,75 | −3 175 | 399 669 |
2013-06-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 900 | 12 688 | −27,86 | 31,07 | −152 249 | 394 233 |
2013-06-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 5 000 | 17 588 | 39,72 | 7,10 | 35 500 | 124 875 |
2013-06-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 250 | 12 588 | −33,18 | 31,07 | −194 196 | 391 126 |
2013-06-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 250 | 18 838 | 49,65 | 9,30 | 58 125 | 175 193 |
2013-06-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −3 750 | 12 588 | −22,95 | 31,07 | −116 517 | 391 126 |
2013-06-13 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 3 750 | 16 338 | 29,79 | 9,14 | 34 275 | 149 329 |
2013-03-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
M - Exercise | X | −6 250 | 56 250 | −10,00 | |||
2013-03-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −6 250 | 12 588 | −33,18 | 24,55 | −153 415 | 308 990 |
2013-03-11 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 250 | 18 838 | 49,65 | 9,30 | 58 125 | 175 193 |
2012-12-21 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (right to buy) |
A - Award | 50 000 | 50 000 | |||||
2012-12-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −3 750 | 15 000 | −20,00 | |||
2012-12-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −6 250 | 62 500 | −9,09 | |||
2012-12-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −10 000 | 12 588 | −44,27 | 19,00 | −190 000 | 239 172 |
2012-12-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 3 750 | 22 588 | 19,91 | 9,14 | 34 275 | 206 454 |
2012-12-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 6 250 | 18 838 | 49,65 | 9,30 | 58 125 | 175 193 |
2012-12-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −4 777 | 30 000 | −13,74 | |||
2012-12-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 777 | 12 588 | −27,51 | 17,00 | −81 209 | 213 996 |
2012-12-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 4 777 | 17 365 | 37,95 | 7,10 | 33 917 | 123 292 |
2012-12-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −2 400 | 34 777 | −6,46 | |||
2012-12-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 400 | 12 588 | −16,01 | 17,04 | −40 896 | 214 500 |
2012-12-06 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 2 400 | 14 988 | 19,07 | 7,10 | 17 040 | 106 415 |
2012-12-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −2 823 | 37 177 | −7,06 | |||
2012-12-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −2 823 | 12 588 | −18,32 | 17,03 | −48 072 | 214 359 |
2012-12-04 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 2 823 | 15 411 | 22,43 | 7,10 | 20 043 | 109 418 |
2012-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −4 916 | 68 750 | −6,67 | |||
2012-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −4 916 | 12 588 | −28,09 | 19,00 | −93 404 | 239 172 |
2012-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 4 916 | 17 504 | 39,05 | 9,30 | 45 719 | 162 787 |
2012-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −1 334 | 73 666 | −1,78 | |||
2012-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −1 334 | 12 588 | −9,58 | 19,00 | −25 346 | 239 172 |
2012-09-12 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 1 334 | 13 922 | 10,60 | 9,30 | 12 406 | 129 475 |
2012-07-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −25 000 | 75 000 | −25,00 | |||
2012-07-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Stock Option (Right to Buy) |
M - Exercise | X | −11 250 | 18 750 | −37,50 | |||
2012-07-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −11 250 | 12 588 | −47,19 | 19,00 | −213 750 | 239 172 |
2012-07-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 11 250 | 23 838 | 89,37 | 9,14 | 102 825 | 217 879 |
2012-07-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
S - Sale | X | −25 000 | 12 588 | −66,51 | 19,00 | −475 000 | 239 172 |
2012-07-18 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
M - Exercise | X | 25 000 | 37 588 | 198,60 | 9,30 | 232 500 | 349 568 |
2012-01-25 |
|
4 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
A - Award | 12 588 | 12 588 | |||||
2009-03-13 | 3 | ALNY |
ALNYLAM PHARMACEUTICALS, INC.
Common Stock |
799 |